Personalized medicine helps doctors learn about a person’s genetic makeup and how their tumor grows. This tumor board discussion will provide an update in the state of the art treatment of oral, head and neck cancers. In addition, “Hot Topics” in immunotherapy, HPV related cancers, thyroid cancer, and proton therapy will be discussed.
Medical Oncologists, Radiation Oncologists, Otolaryngologists, Surgeons, Radiologists, Hematologists, Pathologists, Plastic Surgeons and Oral and Maxillofacial Surgeons.
• Improve clinical decision making, clinical outcomes, and patient experience via a multidisciplinary team approach. Group discussion include prospective patient care management, national treatment guidelines, staging, and options and eligibility for genetic testing, clinical research studies, and supportive care services.
• Develop a comprehensive treatment plan for head and neck oncology patients leveraging imaging and pathology testing results and meet Commission on Cancer accreditation standards compliance
FACULTY & DISCLOSURES:
Guilherme Rabinowits, M.D.
Head and Neck and Cutaneous Medical Oncology
Co-Leader, Head and Neck Disease Management Team
Miami Cancer Institute
Geoffrey Young, M.D., Ph.D., FACS, FSSO
Chief – Head and Neck Surgery
Miami Cancer Institute
Vice Chair – Surgery
Florida International University
Guilherme Rabinowits, M.D., indicated that he is a consultant for Emd Serono, Pfizer, Regeneron, Sanofi, Castle and Merck. He is also a stock/shareholder with Regeneron, and Syros Pharmaceuticals and has indicated that the presentations or discussions will not include off-label or unapproved product usage.
Geoffrey Young, M.D., Ph.D., has indicated that he does not have any relevant relationships with ineligible companies* to disclose and has indicated that the presentations or discussions will not include off-label or unapproved product usage.
All of the relevant financial relationships listed for this/these individual have been mitigated.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*
*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.